{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+The+Countess+of+Mar&min-questionFirstAnswered.=2014-07-17T14%3A20%3A11.251183Z&max-questionFirstAnswered.=2014-10-29T16%3A15%3A22.2220144Z", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMember.label=Biography+information+for+The+Countess+of+Mar&min-questionFirstAnswered.=2014-07-17T14%3A20%3A11.251183Z&max-questionFirstAnswered.=2014-10-29T16%3A15%3A22.2220144Z", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+The+Countess+of+Mar&min-questionFirstAnswered.=2014-07-17T14%3A20%3A11.251183Z&_metadata=all&max-questionFirstAnswered.=2014-10-29T16%3A15%3A22.2220144Z", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+The+Countess+of+Mar&_page=0&min-questionFirstAnswered.=2014-07-17T14%3A20%3A11.251183Z&max-questionFirstAnswered.=2014-10-29T16%3A15%3A22.2220144Z", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+The+Countess+of+Mar&min-questionFirstAnswered.=2014-07-17T14%3A20%3A11.251183Z&max-questionFirstAnswered.=2014-10-29T16%3A15%3A22.2220144Z", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+The+Countess+of+Mar&min-questionFirstAnswered.=2014-07-17T14%3A20%3A11.251183Z&max-questionFirstAnswered.=2014-10-29T16%3A15%3A22.2220144Z", "items" : [{"_about" : "http://data.parliament.uk/resources/93427", "AnsweringBody" : [{"_value" : "Home Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/93427/answer", "answerText" : {"_value" : "<p>The Immigration Rules already provide for doctors here under the Tier 2 skilled work route and working for the UK health system to return to their home countries for short periods to provide support. The Tier 2 rules allow for periods of unpaid leave of up to one month in every 12 month period. There is also nothing in the Immigration Rules to prevent someone on a Tier 2 visa using their annual leave to volunteer in Africa.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1091", "label" : {"_value" : "Biography information for Lord Bates"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Bates"}
        , "dateOfAnswer" : {"_value" : "2014-10-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-10-21T16:30:37.6684195Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "1"}
      , "answeringDeptShortName" : {"_value" : "Home Office"}
      , "answeringDeptSortName" : {"_value" : "Home Office"}
      , "date" : {"_value" : "2014-10-14", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Immigration: West Africa"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government what steps are being taken to reduce the immigration restrictions on doctors from West Africa who currently work in the United Kingdom and who volunteer to return to West Africa temporarily to provide medical support for those suffering from ebola.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL2093"}
    , {"_about" : "http://data.parliament.uk/resources/93428", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/93428/answer", "answerText" : {"_value" : "<p>The Food Standards Agency (FSA) advise that the paper is still in the peer-review process. Publication in a scientific journal is expected and is the preferable route as it makes the data more readily available to the scientific community. Once this happens the FSA will publish the final report on foodbase, the FSA\u2019s open access repository.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
        }
        , "answeringMemberPrinted" : {"_value" : "Earl Howe"}
        , "dateOfAnswer" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-10-24T11:26:46.3259129Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-14", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Aspartame"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government when they intend to publish the results of the Hull trial on aspartame on the Food Standards Agency website.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL2094"}
    , {"_about" : "http://data.parliament.uk/resources/79197", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/79197/answer", "answerText" : {"_value" : "<p>Use of a sample type not indicated by the manufacturer would be considered to be off label use of the device. This off label use is not regulated by the Medicines and Healthcare products Regulatory Agency and would be the responsibility of the laboratory.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
        }
        , "answeringMemberPrinted" : {"_value" : "Earl Howe"}
        , "dateOfAnswer" : {"_value" : "2014-07-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-07-29T13:16:10.1285003Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-07-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Lyme Disease"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government, further to the Written Answer by Earl Howe on 25 June 2012 (WA 21\u20132), whether they consider that the use of the CE-marked Trinity Biotech EU Lyme western blot test, when used with cerebrospinal fluid, would constitute \"use of an in-house test\" as defined by the Medical and Healthcare Products Regulatory Agency guidance.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL1358"}
    , {"_about" : "http://data.parliament.uk/resources/78303", "AnsweringBody" : [{"_value" : "Department for Business, Innovation and Skills"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/78303/answer", "answerText" : {"_value" : "<table><tbody><tr><td colspan=\"5\"><p>Data showing the volume (kilograms) of UK imports of aspartame during 2000-2013 is given in Table 1 below. The figures are sourced from HMRC\u2019s Overseas Trade Statistics database.<\/p><p><strong>Table 1: UK imports of aspartame (HS code 21069092)<\/strong><\/p><\/td><td> <\/td><\/tr><tr><td><strong> <\/strong><\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>Year<\/td><td>Net mass (kgs)<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>2013<\/td><td>76,393,895<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>2012<\/td><td>85,600,024<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>2011<\/td><td>63,298,987<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>2010<\/td><td>54,483,436<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>2009<\/td><td>51,466,542<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>2008<\/td><td>58,734,046<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>2007<\/td><td>50,538,317<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>2006<\/td><td>59,274,993<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>2005<\/td><td>56,112,033<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>2004<\/td><td>63,320,625<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>2003<\/td><td>61,259,916<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>2002<\/td><td>43,939,777<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>2001<\/td><td>40,554,490<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td>2000<\/td><td>29,438,869<\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td> <\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td colspan=\"4\">Source: HMRC Overseas Trade Statistics database<\/td><td> <\/td><td> <\/td><\/tr><tr><td colspan=\"6\">Note: HS 21069092 = Food preparations, n.e.s., not containing milkfats,<\/td><\/tr><tr><td colspan=\"6\">sucrose, isoglucose starch or glucose or containing, by weight, &lt; 1,5% milkfat,<\/td><\/tr><tr><td colspan=\"5\">&lt; 5% sucrose or isoglucose, &lt; 5% glucose or &lt; 5% starch&quot; only.<\/td><td> <\/td><\/tr><tr><td> <\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><tr><td> <\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><td> <\/td><\/tr><\/tbody><\/table>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4278", "label" : {"_value" : "Biography information for Lord Livingston of Parkhead"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Livingston of Parkhead"}
        , "dateOfAnswer" : {"_value" : "2014-07-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-07-22T16:58:32.6543938Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "26"}
      , "answeringDeptShortName" : {"_value" : "Business, Innovation and Skills"}
      , "answeringDeptSortName" : {"_value" : "Business, Innovation and Skills"}
      , "date" : {"_value" : "2014-07-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Aspartame"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government how many kilograms of aspartame were imported into the United Kingdom in each year from 2000 to 2013 inclusive.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL1193"}
    , {"_about" : "http://data.parliament.uk/resources/78304", "AnsweringBody" : [{"_value" : "Cabinet Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/78304/answer", "answerText" : {"_value" : "<p>The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1816", "label" : {"_value" : "Biography information for Lord Wallace of Saltaire"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Wallace of Saltaire"}
        , "attachment" : {"_about" : "http://data.parliament.uk/resources/78304/answer/attachment/1", "fileName" : {"_value" : "PQ HL1194 ONS 323.pdf"}
          , "title" : "ONS Letter to PEER"}
        , "dateOfAnswer" : {"_value" : "2014-07-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-07-21T14:28:33.8065954Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "53"}
      , "answeringDeptShortName" : {"_value" : "Cabinet Office"}
      , "answeringDeptSortName" : {"_value" : "Cabinet Office"}
      , "date" : {"_value" : "2014-07-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Alzheimer's Disease"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government how many deaths in the United Kingdom were attributed to Alzheimer\u2019s disease in 1970, 1982 and 2013.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL1194"}
    , {"_about" : "http://data.parliament.uk/resources/77264", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/77264/answer", "answerText" : {"_value" : "<p>The Trinity Biotech blot has been in use since 2007 by the former Health Protection Agency's Lyme Borreliosis Unit for testing cerebrospinal fluid (CSF) and proved very reliable. It has also been used in this way by other laboratories in Europe. However, CSF antibodies will not be present if there is no evidence of any other antibodies in the serum. Data is not collected centrally on specific samples from patients as the final diagnosis is made by the clinician on the basis of the test results and the clinical presentation.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
        }
        , "answeringMemberPrinted" : {"_value" : "Earl Howe"}
        , "dateOfAnswer" : {"_value" : "2014-07-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-07-24T12:31:17.2846277Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-07-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Lyme Disease"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government when the testing of the cerebrospinal fluid of patients suspected of having Lyme disease using the Trinity Biotech kit at the Health Protection Agency\u2019s Lyme Borreliosis Unit began; how many patients' samples were tested in that way; and how many patients were recorded as being positive over that period of time.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL998"}
    , {"_about" : "http://data.parliament.uk/resources/77265", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/77265/answer", "answerText" : {"_value" : "<p>The former Health Protection Agency's Lyme Borreliosis Unit (HPA LBU) was accredited by Clinical Pathology Accreditation who had access to, and was able to review, all the standard operating procedures of the unit.<\/p><p> <\/p><p>The Trinity Biotech Lyme Western Blot is a qualitative in vitro assay for the detection of Immunoglobulin (IgG or IgM) antibodies in human samples against specific antigens/proteins of <em>Borrelia afzelii, Borrelia garinii and Borrelia burgdorferi<\/em>. The Trinity Biotech Lyme Western Blot is intended as a confirmatory assay for use in testing human samples which have been previously found to be positive or equivocal using an Enzyme Immunoassay and Immunofluroescent Assay or other appropriate screening method. Positive second-tier results are supportive evidence of infection with <em>B. burgdorferi<\/em>. The diagnosis of Lyme disease should be made based on history and symptoms (such as erythema migrans), and other laboratory data, in addition to the presence of antibodies to <em>B. burgdorferi<\/em>. The Trinity Biotech blot has been in use since 2007 by the former HPA\u2019s LBU for testing cerebrospinal fluid (CSF) and proved very reliable. This technique has also been in use widely across Europe during this period as a diagnostic test using CSF as a sample to support the diagnosis of neuroborreliosis.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
        }
        , "answeringMemberPrinted" : {"_value" : "Earl Howe"}
        , "dateOfAnswer" : {"_value" : "2014-07-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-07-24T12:32:59.6647091Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-07-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Lyme Disease"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government whether, in December 2011, the Clinical Pathology Accreditation Service was made aware of modifications by the Health Protection Agency\u2019s Lyme Borreliosis Unit to the Trinity Biotech immunoblot kit to be used for testing human cerebrospinal fluid.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL999"}
    , {"_about" : "http://data.parliament.uk/resources/77266", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/77266/answer", "answerText" : {"_value" : "<p>The former Health Protection Agency's Lyme Borreliosis Unit adhered to legislation related to diagnostic testing. The Trinity Biotech Lyme Western Blot technique was widely used in Europe at that time for serum and samples. Controls were run with each batch of the test to verify the tests accuracy and sensitivity. Quality assurance samples were run to ensure independent validation of the results.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
        }
        , "answeringMemberPrinted" : {"_value" : "Earl Howe"}
        , "dateOfAnswer" : {"_value" : "2014-07-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-07-24T14:21:30.3706696Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-07-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Lyme Disease"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government what evidence existed to show that the Health Protection Agency\u2019s Lyme Borreliosis Unit (LBU) conformed with European Union and United Kingdom legislation for the use of the Trinity Biotech kit for <i>in vitro<\/i> testing when used with cerebrospinal fluid; and what testing was carried out by the LBU to verify that the use of that test kit was suitable, and sufficiently sensitive, for the detection of European and United Kingdom species of Borrelia infections in cerebrospinal fluid.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL1000"}
    , {"_about" : "http://data.parliament.uk/resources/77267", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/77267/answer", "answerText" : {"_value" : "<p>The former Health Protection Agency's (HPA) Lyme Borreliosis Unit adhered to the HPA\u2019s published guidelines on Commercial and In-House Diagnostic Tests.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
        }
        , "answeringMemberPrinted" : {"_value" : "Earl Howe"}
        , "dateOfAnswer" : {"_value" : "2014-07-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-07-24T13:24:08.7476509Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-07-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Lyme Disease"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government whether the Health Protection Agency\u2019s Lyme Borreliosis Unit adhered to the Health Protection Agency's published guidelines on <i>Commercial and In-House Diagnostic Tests: Evaluations and Validations<\/i> in carrying out testing of cerebrospinal fluid of patients suspected of having Lyme disease using the Trinity Biotech kit.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL1001"}
    , {"_about" : "http://data.parliament.uk/resources/77268", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/77268/answer", "answerText" : {"_value" : "<p>The former Health Protection Agency's Lyme Borreliosis Unit (HPA LBU) informed requesting clinicians but not patients of the results on cerebrospinal fluid (CSF) and also provided a clinical interpretive service to the requesting clinician. Referring laboratories and clinicians managing patients with Lyme disease were aware of the limitations of diagnostic tests for serum and CSF through publications and educational meetings. It is the role of the requesting clinician to be guided by the interpretation of the laboratory result and to use these results in the light of the clinical presentation to make a diagnosis and a management plan for individual patients. It is also important to note that the former HPA\u2019s LBU performed diagnostic tests on samples referred by other laboratories<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
        }
        , "answeringMemberPrinted" : {"_value" : "Earl Howe"}
        , "dateOfAnswer" : {"_value" : "2014-07-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-07-24T13:33:24.7350156Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-07-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Lyme Disease"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government whether the Health Protection Agency's Lyme Borreliosis Unit informed clinicians and patients of test results on cerebrospinal fluid in accordance with Medicines and Healthcare Products Regulatory Agency guidance in carrying out testing of cerebrospinal fluid of patients suspected of having Lyme disease using the Trinity Biotech kit.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL1002"}
    ], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+The+Countess+of+Mar&_page=1&min-questionFirstAnswered.=2014-07-17T14%3A20%3A11.251183Z&max-questionFirstAnswered.=2014-10-29T16%3A15%3A22.2220144Z", "page" : 0, "startIndex" : 1, "totalResults" : 11, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}